Drugs Made In America Acquisition II Corp. (DMII)
| Market Cap | 647.83M |
| Revenue (ttm) | n/a |
| Net Income | 13.02M |
| EPS | 0.24 |
| Shares Out | 63.70M |
| PE Ratio | 41.56 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 578 |
| Open | 10.17 |
| Previous Close | 10.17 |
| Day's Range | 10.17 - 10.17 |
| 52-Week Range | 9.86 - 10.21 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About DMII
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
News
Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering
Drugs Made In America Acquisition II (Nasdaq: DMIIU) announced today the pricing yesterday of its initial public offering of 50,000,000 units at $10.00 per unit.
SPAC Drugs Made In America Acquisition II files for a $500 million IPO, targeting pharmaceuticals
Drugs Made In America Acquisition II, a blank check company targeting the pharmaceutical industry, filed on Monday with the SEC to raise up to $500 million in an initial public offering.
Drugs Made In America Acquisition II IPO Registration Document (S-1)
Drugs Made In America Acquisition II has filed to go public with an IPO on the NASDAQ.